|
|
???tair.name??? >
???browser.page.title.author???
|
"rha sy"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國家衛生研究院 |
2025-01-27 |
Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma,
|
Janjigian, YY;Van Laarhoven, HWM;Rha, SY;Kozlov, V;Oh, D;Gravina, A;Rapatoni, L;Shoji, H;Hofheinz, RD;Chen, LT;Ford, H;Chenard-Poirier, M;de Giorgio-Miller, V;Chang, YT;Anadu, O;Lee, J |
| 國家衛生研究院 |
2024-09 |
Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)
|
Janjigian, YY;van Laarhoven, HWM;Rha, SY;Kozlov, V;Oh, DY;Gravina, A;Rapatoni, L;Shoji, H;Hofheinz, RD;Chen, LT;Ford, HER;Chenard-Poirier, M;Raoufmoghaddam, S;Lloyd, C;Zhang, C;Mateo, C;Lee, J |
| 國家衛生研究院 |
2024-08-20 |
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri
|
Boku, N;Omori, T;Shitara, K;Sakuramoto, S;Yamaguchi, K;Kato, K;Kadowaki, S;Tsuji, K;Ryu, MH;Oh, DY;Oh, SC;Rha, SY;Lee, KW;Chung, IJ;Sym, SJ;Chen, LT;Chen, JS;Bai, LY;Nakada, T;Hagihara, S;Makino, R;Nishiyama, E;Kang, YK |
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
